Genprex bets on a one-time gene therapy for diabetes (Part 3 of 3)
In part three of our series, I spoke with Ryan Confer, President and CEO of Genprex, about the company’s move from cancer into diabetes.
In part three of our series, I spoke with Ryan Confer, President and CEO of Genprex, about the company’s move from cancer into diabetes.